Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application.General Protocolsare available in the Technical Information section on our website.

Data Example

Western BlotView Larger

Detection of Human SUMO3 by Western Blot.Western blot shows lysates of SUMO3. PVDF membrane was probed with 0.5 µg/mL of Rat Anti-Human SUMO3 Monoclonal Antibody (Catalog # A-720) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for SUMO3 at approximately 16-18 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Preparation and Storage

Background: SUMO3

Small Ubiquitin­like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post­translational modification process termed SUMOylation. Unlike ubiquitination, which targets proteins for degradation, SUMOylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All human SUMO proteins share a conserved ubiquitin-like domain and a C-terminal diglycine cleavage/attachment site. Human SUMO3, also known as SMT3A, is synthesized as a 103 amino acid (aa), 11.5 kDa propeptide that contains an 11 aa C­terminal prosegment. Following prosegment cleavage, the C­terminal glycine may be enzymatically attached to a lysine on a target protein. Human SUMO3 shares 83% sequence identity with SUMO3 from mouse. SUMO3 also has very high sequence homology to SUMO2 and SUMO4, 87% and 75%, respectively. SUMO3 shares only 47% sequence identity to SUMO1.

Product Datasheets

Related Research Areas

• NFkB Pathway
• Ubiquitin-like Modifiers (UBLs) and Regulators